Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00440609

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab

Sponsor: Philip J. ferrone, M.D.

Conditions Clinically Significant Diabetic Macular Edema

Interventions ranibizumab

Updated 6 times since 2017 Last updated: Aug 1, 2013 Started: Mar 31, 2007 Primary completion: Nov 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00440609, this PHASE1/PHASE2 trial focuses on Clinically Significant Diabetic Macular Edema and remains completed. Sponsored by Philip J. ferrone, M.D., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Philip J. ferrone, M.D.

Data source: Long Island Vitreoretinal Consultants

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Great Neck, United States
• Hauppauge, United States